Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

US9758520B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Lothar Schwink · Stadtallendorf, DE
• Christian Buning · Frankfurt am Main, DE
• Heiner Glombik · Hofheim, DE
• Matthias Gossel · Frankfurt am Main, DE
• Dieter Kadereit · Kelkheim, DE
• Nis Halland · Frankfurt am Main, DE
• Matthias Lohmann · Frankfurt am Main, DE
• Christoph Pöverlein · Frankfurt am Main, DE
• Kurt Ritter · Heidelberg, DE

Key dates

• Filing date: Oct 3, 2016
• Grant date: Sep 12, 2017
• Expiry date: Oct 3, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to substituted fused heterocyclic compounds.The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.